This study was designed to compare the safety and efficacy of sirolimus-eluting stents
(SESs) to paclitaxel-eluting stents (PESs) in percutaneous intervention of saphenous
vein graft (SVG) lesions. SVGs develop atherosclerosis at high rates and often require
repeat revascularization. Percutaneous intervention with drug-eluting stents has become
the preferred method of revascularization due to higher restenosis with bare metal
stents and increased morbidity and mortality with repeat coronary artery bypass grafting.
We sought to compare the rate of major adverse cardiac events and stent thrombosis
between SESs and PESs in patients undergoing SVG intervention. A multicenter analysis
of 172 patients with SVG lesions treated with SESs or PESs was performed. The 30-day
and 1-year clinical outcomes of 102 patients receiving SESs were compared to those
of 70 patients receiving PESs. There was no significant difference in baseline demographic,
angiographic, and procedural characteristics between the SES and PES treatment groups.
There was no statistical difference in major adverse cardiac events at 30 days and
at 1 year (hazard ratio [HR] 1.58, 95% confidence interval [CI] 0.77 to 3.23, log-rank
p = 0.21). There was also no difference in survival (HR 1.28, 95% CI 0.39 to 4.25,
log-rank p = 0.69) or target vessel revascularization (HR 2.54, 95% CI 0.84 to 7.72,
log-rank p = 0.09). In conclusion, this multicenter analysis of real-world patients
demonstrated that SESs and PESs have similar clinical outcomes when used in SVG intervention.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years.J Am Coll Cardiol. 1996; 28: 616-626
- Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts.J Thorac Cardiovasc Surg. 1985; 89: 248-258
- Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery.J Am Coll Cardiol. 2004; 44: 2149-2156
- Contemporary results show repeat coronary artery bypass grafting remains a risk factor for operative mortality.Ann Thorac Surg. 2009; 87: 1386-1391
- Coronary angioplasty versus repeat coronary artery bypass grafting for patients with previous bypass surgery.J Am Coll Cardiol. 1996; 28: 1140-1146
- Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts.N Engl J Med. 1997; 337: 740-747
- Comparison of stenting and balloon angioplasty for narrowings in aortocoronary saphenous vein conduits in place for more than five years.Am J Cardiol. 1997; 79: 13-18
- Serial angiographic follow-up after Palmaz-Schatz stent implantation: comparison with conventional balloon angioplasty.J Am Coll Cardiol. 1993; 21: 1557-1563
- Stent thrombosis in randomized clinical trials of drug-eluting stents.N Engl J Med. 2007; 356: 1020-1029
- Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials.JAMA. 2005; 294: 819-825
- A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease.Br J Clin Pharmacol. 2006; 61: 720-726
- A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.J Am Coll Cardiol. 2007; 50: 1373-1380
- Comparative safety and efficacy of a sirolimus-eluting versus paclitaxel-eluting stent: a meta-analysis.Am Heart J. 2008; 155: 630-639
- A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions.J Am Coll Cardiol. 2009; 53: 919-928
- Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts.J Am Coll Cardiol. 2006; 48: 2423-2431
- Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts.J Am Coll Cardiol. 2007; 50: 261-267
- Efficacy of sirolimus-eluting stents as compared to paclitaxel-eluting stents for saphenous vein graft intervention.J Interv Cardiol. 2006; 19: 121-125
- Treatment of saphenous vein graft lesions with paclitaxel- and sirolimus-eluting stents: comparison of short- and long-term clinical outcomes.Anadolu Kardiyol Derg. 2008; 8: 431-436
- Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data).Am J Cardiol. 2005; 95: 1469-1472
- What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: A meta-analysis.J Am Coll Cardiol. 2005; 45: 941-946
- Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.J Am Coll Cardiol. 2005; 45: 954-959
- Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials.Am J Med. 2006; 119: 1056-1061
- Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.Lancet. 2007; 369: 667-678
- Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.N Engl J Med. 2007; 356: 998-1008
Article info
Publication history
Accepted:
March 11,
2010
Received in revised form:
March 11,
2010
Received:
January 26,
2010
Identification
Copyright
© 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Could Paclitaxel-Eluting Stents Be Superior to Sirolimus-Eluting Stents for the Treatment of Saphenous Vein Graft Lesions?American Journal of CardiologyVol. 106Issue 9
- PreviewWe read with great interest the important and timely study by Lee et al,1 who compared sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) for the treatment of saphenous vein graft lesions in the Southern California Registry. The investigators concluded that SES and PES had similar 1-year clinical outcomes. Although their interpretation of the study findings is correct, we would like to propose an alternative interpretation: that PES may provide superior results compared with SES in saphenous vein grafts, but this was not demonstrated in the investigators' study because of small sample size.
- Full-Text
- Preview
